PH12021552841A1 - Methods of treating cancer using prmt5 inhibitors - Google Patents
Methods of treating cancer using prmt5 inhibitorsInfo
- Publication number
- PH12021552841A1 PH12021552841A1 PH1/2021/552841A PH12021552841A PH12021552841A1 PH 12021552841 A1 PH12021552841 A1 PH 12021552841A1 PH 12021552841 A PH12021552841 A PH 12021552841A PH 12021552841 A1 PH12021552841 A1 PH 12021552841A1
- Authority
- PH
- Philippines
- Prior art keywords
- days
- methods
- administering
- prmt5
- subsequent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150097768 prmt5 gene Proteins 0.000 title 1
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 2
- 229940125897 PRMT5 inhibitor Drugs 0.000 abstract 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 2
- DBSMLQTUDJVICQ-CJODITQLSA-N onametostat Chemical group NC1=C2C=CN([C@@H]3C[C@H](CCC4=CC=C5C=C(Br)C(N)=NC5=C4)[C@@H](O)[C@H]3O)C2=NC=N1 DBSMLQTUDJVICQ-CJODITQLSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858076P | 2019-06-06 | 2019-06-06 | |
| EP19193850 | 2019-08-27 | ||
| PCT/EP2020/065639 WO2020245365A1 (en) | 2019-06-06 | 2020-06-05 | Methods of treating cancer using prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552841A1 true PH12021552841A1 (en) | 2022-10-03 |
Family
ID=70922068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552841A PH12021552841A1 (en) | 2019-06-06 | 2020-06-05 | Methods of treating cancer using prmt5 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11571437B2 (enExample) |
| EP (1) | EP3980019A1 (enExample) |
| JP (1) | JP7590351B2 (enExample) |
| KR (1) | KR20220017989A (enExample) |
| CN (1) | CN113966232A (enExample) |
| AU (1) | AU2020286961A1 (enExample) |
| BR (1) | BR112021024469A2 (enExample) |
| CA (1) | CA3142825A1 (enExample) |
| IL (1) | IL288665A (enExample) |
| JO (1) | JOP20210320A1 (enExample) |
| MA (1) | MA56095A (enExample) |
| MX (1) | MX2021014944A (enExample) |
| PH (1) | PH12021552841A1 (enExample) |
| SG (1) | SG11202112439YA (enExample) |
| TW (1) | TW202112375A (enExample) |
| WO (1) | WO2020245365A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153161A1 (en) * | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CN115161341B (zh) * | 2022-06-10 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| WO2003070739A1 (en) | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| EP1645561A1 (en) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
| US20080033172A1 (en) | 2003-12-19 | 2008-02-07 | Koronis Pharmaceuticals, Incorporated | Mutagenic Heterocycles |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| WO2011075665A2 (en) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012083170A1 (en) | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| JP6510485B2 (ja) * | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019006414A2 (pt) | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| SG11201907607VA (en) | 2017-02-27 | 2019-09-27 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| MX2020005944A (es) | 2017-12-08 | 2020-08-24 | Janssen Pharmaceutica Nv | Analogos espirobiciclicos novedosos. |
-
2020
- 2020-06-04 TW TW109118748A patent/TW202112375A/zh unknown
- 2020-06-05 KR KR1020227000036A patent/KR20220017989A/ko not_active Ceased
- 2020-06-05 AU AU2020286961A patent/AU2020286961A1/en not_active Abandoned
- 2020-06-05 EP EP20729788.8A patent/EP3980019A1/en not_active Withdrawn
- 2020-06-05 MX MX2021014944A patent/MX2021014944A/es unknown
- 2020-06-05 MA MA056095A patent/MA56095A/fr unknown
- 2020-06-05 JP JP2021571834A patent/JP7590351B2/ja active Active
- 2020-06-05 CA CA3142825A patent/CA3142825A1/en active Pending
- 2020-06-05 BR BR112021024469A patent/BR112021024469A2/pt unknown
- 2020-06-05 US US16/893,477 patent/US11571437B2/en active Active
- 2020-06-05 SG SG11202112439YA patent/SG11202112439YA/en unknown
- 2020-06-05 WO PCT/EP2020/065639 patent/WO2020245365A1/en not_active Ceased
- 2020-06-05 CN CN202080043244.1A patent/CN113966232A/zh active Pending
- 2020-06-05 PH PH1/2021/552841A patent/PH12021552841A1/en unknown
-
2021
- 2021-12-01 JO JOP/2021/0320A patent/JOP20210320A1/ar unknown
- 2021-12-05 IL IL288665A patent/IL288665A/en unknown
-
2023
- 2023-01-26 US US18/160,246 patent/US20230241087A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535406A (ja) | 2022-08-08 |
| TW202112375A (zh) | 2021-04-01 |
| CA3142825A1 (en) | 2020-12-10 |
| JP7590351B2 (ja) | 2024-11-26 |
| WO2020245365A1 (en) | 2020-12-10 |
| CN113966232A (zh) | 2022-01-21 |
| BR112021024469A2 (pt) | 2022-01-18 |
| JOP20210320A1 (ar) | 2023-01-30 |
| SG11202112439YA (en) | 2021-12-30 |
| US20230241087A1 (en) | 2023-08-03 |
| MX2021014944A (es) | 2022-01-24 |
| AU2020286961A1 (en) | 2022-02-03 |
| US20200384006A1 (en) | 2020-12-10 |
| IL288665A (en) | 2022-02-01 |
| EP3980019A1 (en) | 2022-04-13 |
| KR20220017989A (ko) | 2022-02-14 |
| US11571437B2 (en) | 2023-02-07 |
| MA56095A (fr) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| JOP20210320A1 (ar) | طرق علاج السرطان باستخدام مثبطات prmt5 | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| JOP20210172A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| MX2023010016A (es) | Derivado de pirimidina con actividad inhibidora contra las proteina cinasas y composicion farmaceutica terapeutica que incluye el mismo. | |
| EA202193330A1 (ru) | Способы лечения рака с использованием ингибиторов prmt5 | |
| CL2022003477A1 (es) | Compuesto de alquenilpirimidina, método de preparación del mismo y aplicación del mismo | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| MX2023012030A (es) | Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4). | |
| RU2015152175A (ru) | Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax |